Loading...

Brilliant Violet 510™ anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_BV510_CD8a_Antibody_FC_082312
C57BL/6 mouse splenocytes were stained with CD3 APC and CD8a (clone 53-6.7) Brilliant Violet 510™.
  • 53-6.7_BV510_CD8a_Antibody_FC_082312
    C57BL/6 mouse splenocytes were stained with CD3 APC and CD8a (clone 53-6.7) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Save
100751 125 µL ¥36,300
100752 50 µg ¥51,040
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  2. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  3. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  4. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  5. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  6. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  7. Miró L, et al. 2022. Cancers (Basel). 14: . PubMed
  8. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  9. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  10. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  11. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  12. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  13. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
  14. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  15. Wu R, et al. 2022. Nat Immunol. 23:1536. PubMed
  16. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  17. Giampaolo S, et al. 2023. iScience. 26:106234. PubMed
  18. Byrne PO, et al. 2023. Nat Commun. 14:1494. PubMed
  19. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  20. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  21. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  22. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  23. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  24. Li SX, et al. 2019. PLoS Pathog. 15:e1007611. PubMed
  25. Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed
  26. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  27. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  28. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  29. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  30. Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed
  31. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  32. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  33. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  34. Wang D, et al. 2018. Immunity. 48:659. PubMed
  35. Wang C, et al. 2015. Sci Rep. 5: 14124. PubMed
  36. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  37. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  38. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  39. Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed
  40. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  41. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  42. Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed
  43. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  44. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  45. Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed
  46. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  47. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  48. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  49. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  50. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  51. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  52. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  53. Koivisto CS, et al. 2020. Neoplasia. 1.252777778. PubMed
  54. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  55. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  56. Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed
  57. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  58. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  59. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  60. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  61. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  62. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  63. Liu CY, et al. 2020. Cell Rep. 33:108275. PubMed
  64. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  65. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  66. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  67. Cosentino K, et al. 2022. Mol Cell. 82:933. PubMed
  68. Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed
  69. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  70. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  71. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  72. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  73. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  74. Souza SP, et al. 2021. PLoS Pathog. 17:e1010081. PubMed
  75. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  76. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  77. Cosway EJ, et al. 2017. J Exp Med. 214:3183. PubMed
  78. Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed
  79. Loo CS, et al. 2020. Immunity. 53:143. PubMed
  80. Zhu D, et al. 2017. Stem Cell Res Ther. 0.511805556. PubMed
  81. Fowler AM et al. 2018. Cell host & microbe. 24(5):743-750 . PubMed
  82. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  83. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  84. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  85. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  86. Soukup K, et al. 2017. Sci Rep. 10.1038/s41598-017-12208-7. PubMed
  87. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  88. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  89. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  90. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  91. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  92. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  93. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  94. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  95. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  96. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  97. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  98. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  99. Tao Z, et al. 2022. Cells. 11:. PubMed
  100. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  101. Teijeira á, et al. 2020. Immunity. 52(5):856-871. PubMed
  102. Wang T, et al. 2015. Proc Natl Acad Sci U S A. 112:440. PubMed
  103. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  104. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  105. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  106. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  107. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  108. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID
AB_2563057 (BioLegend Cat. No. 100751)
AB_2563057 (BioLegend Cat. No. 100752)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account